This trial will test a new drug's safety and effectiveness in people. It has two parts and will be conducted at multiple sites.
- Non-Hodgkin Lymphoma
- Chronic B-Cell Leukemia
2 Primary · 5 Secondary · Reporting Duration: Through study completion, an average of 1 year
2 Treatment Groups
Dose Expansion Phase (Part 2)
1 of 2
Dose Escalation Phase (Part 1)
1 of 2
54 Total Participants · 2 Treatment Groups
Primary Treatment: Dose Expansion Phase (Part 2) · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is this trial still recruiting participants?
"According to clinicaltrials.gov, this trial is actively seeking participants. It was originally posted on February 13th of 2023 and has most recently been updated as of February 15th of the same year." - Anonymous Online Contributor
Has the Dose Expansion Phase (Part 2) of this treatment been given regulatory approval?
"The amount of clinical data available for Dose Expansion Phase (Part 2) is limited, so it was rated a 1 on our team's scale. This indicates that this trial has only reached the initial phase in demonstrating efficacy and safety." - Anonymous Online Contributor
What is the aggregate amount of participants included in this experiment?
"Yes, the information on clinicaltrials.gov confirms that this research is actively looking for participants. This trial was posted online on February 13th 2023 and latest updated two days later. Currently 54 individuals need to be recruited from 9 varied sites." - Anonymous Online Contributor
How many medical facilities have been chosen to administer this experiment?
"Patients can access this trial at 9 different sites such as Emory University Hospital in Atlanta, AMR Kansas City in Kansas City and Summit Medical Group in Florham Park. An additional 6 locations are also available for patients to receive the treatment." - Anonymous Online Contributor
What are the essential aims of this research endeavor?
"The study's sponsor, Ono Pharmaceutical Co. Ltd., is basing their primary outcome measure on the Maximum Tolerated Dose (MTD), which will be estimated over an average one-year interval. Additionally, they'll also evaluate secondary outcomes such as Antitumor Activity of ONO-7018 through Overall Response Rate (ORR) and Progression Free Survival (PFS). Lastly, they intend to assess overall survival in relation to this medication." - Anonymous Online Contributor